Quantum BioPharma is trading at $2.75, up 11.44% before the October 19, 2026 session, with no clear new company-specific announcement identified to explain the gain. - The Thermo Fisher Phase 2 trial agreement dates to October 6; the lawsuit update describes an October 8 court action. Neither establishes a fresh catalyst. - Sector context is negative, with biotech down 3.65%, opposite to Quantum BioPharma’s move. - No pre-market volume data was provided.